Biologic Drug Lymphoma Risk: Why Dupixent Isn’t the First

Last updated: October 2026

Dupixent is not the first immune-targeting drug to face questions about lymphoma. Over the past 20 years, the FDA has reviewed lymphoma reports for eczema creams, TNF-blocker biologics and JAK inhibitor pills. Some of those reviews led to boxed warnings. Dupixent’s lawsuits follow a familiar pattern, but its science and its label are different. Looking at that history can help you understand biologic drug lymphoma risk without overreacting to headlines or brushing off real questions about your own treatment.

This post looks at biologic drug lymphoma risk through history. It explains what happened before and what those cases can and cannot tell us about Dupixent.

Why immune drugs and lymphoma keep coming up

Lymphoma is a cancer of lymphocytes, the white blood cells that are part of the immune system. Drugs that change how the immune system works naturally raise the question: could they affect how these cells grow?

There are a few reasons this question keeps appearing:

• Biology: The immune system helps find and clear abnormal cells. Drugs that weaken or redirect it may, in theory, change that process.
• The diseases themselves: Some conditions treated with these drugs, like severe eczema or rheumatoid arthritis, may carry their own higher lymphoma risk. That makes cause and effect hard to untangle.
• Look-alike conditions: Some lymphomas mimic the very disease being treated. Cutaneous T-cell lymphoma (CTCL) can look like eczema for years.

Because of these overlaps, a safety signal is the start of an investigation, not the end of one.

The eczema creams: Elidel and Protopic

The first big lymphoma debate in eczema care involved two creams, Elidel (pimecrolimus) and Protopic (tacrolimus). These are topical calcineurin inhibitors, not biologics, but they target the same disease as Dupixent.

In January 2006, the FDA approved a boxed warning for both products. As Dermatology Times reported, the FDA said it had received “rare reports of cancer (skin and lymphoma)” in patients who used them. At the same time, investigators had found no causal link between the creams and cancer.

The lesson: a warning can be added based on concern and reports, even before causation is proven. Later research and debate continued for years.

TNF blockers: the first wave of biologic concerns

TNF blockers were among the first widely used biologic drugs. They include Remicade, Enbrel, Humira, Cimzia and Simponi. They treat conditions such as rheumatoid arthritis, Crohn’s disease and psoriasis.

According to the FDA’s 2011 safety communication, the agency reviewed reports of cancer in children and young adults on TNF blockers in June 2008, August 2009 and April 2011. In November 2011, it required the makers to do in-depth follow-up of malignancy reports in patients 30 and younger.

The FDA also flagged a rare, aggressive lymphoma called hepatosplenic T-cell lymphoma (HSTCL). It was reported mostly in teens and young adults taking TNF blockers together with azathioprine or mercaptopurine.

What made TNF blockers different

TNF blockers broadly suppress part of the immune system. That is one reason infections and cancer became part of their warnings. The concern was tied to a clear biological theory about weakened immune defenses.

JAK inhibitors: warnings based on a large safety trial

JAK inhibitors are pills that block signals inside immune cells. In September 2021, the FDA required new warnings for Xeljanz, Olumiant and Rinvoq. They cover serious heart-related events, cancer, blood clots and death.

This action came from a large randomized safety trial in rheumatoid arthritis patients 50 and older with heart risk factors. The FDA said “lymphomas and lung cancers were observed at a higher rate” in patients on Xeljanz than in those on TNF blockers.

The lesson here is different. A randomized trial designed to study safety gave regulators stronger evidence than reports or database studies alone.

Where Dupixent fits in this history

Dupixent (dupilumab) is a biologic, but it works in a narrower way than TNF blockers. It blocks signals from two immune messengers, interleukin-4 and interleukin-13, which drive allergic-type inflammation. It is not considered a broad immune suppressant. That is one reason the lymphoma question is being studied so closely.

Still, Dupixent now faces its own lymphoma questions:

• In its October–December 2024 signals report, the FDA listed CTCL as a potential signal for Dupixent. It said it is evaluating the need for regulatory action.
• As of the label record updated in August 2026, Dupixent’s Warnings and Precautions section does not mention lymphoma.
• Database studies have reported higher CTCL rates in Dupixent users. Other studies have not found a clear increase compared with other treatments.
• In June 2026, federal CTCL lawsuits were combined into MDL No. 3180 in New Jersey. The companies deny the claims.

A key difference: unmasking vs causing

With TNF blockers, the worry was mainly that weakened immunity let cancers grow. With Dupixent, one central question is whether some patients had early CTCL that looked like eczema. Researchers are asking whether the drug may cause CTCL, speed up hidden CTCL, or simply be given to people whose lymphoma had not been diagnosed yet. Each answer could affect the lawsuits differently.

What this history means for patients

Past cases offer a few practical takeaways. None of them predict how the Dupixent cases will end.

• Signals take time to resolve. FDA reviews of TNF blockers ran from 2008 to 2011 and beyond. The Dupixent review is still open.
• Labels can change. Warnings were added for eczema creams, TNF blockers and JAK inhibitors. Whether Dupixent’s label changes is not yet known.
• Correlation is not causation. The Elidel and Protopic warning came before any proven link. Courts will look closely at the quality of Dupixent science.
• Your records matter. In every one of these debates, timing mattered. When did symptoms start? When did treatment begin? When was the diagnosis made?
• Different evidence carries different weight. Individual reports, database studies and randomized trials are not equal. The JAK inhibitor warnings rested on a trial built to study safety. The Dupixent debate so far rests mostly on reports and health-record studies.

Do not stop Dupixent or any other medicine without talking to your doctor. For many people, these drugs offer real benefits, and your doctor can help weigh your personal risks.

How Researchers Measure Biologic Drug Lymphoma Risk

The history above shows that not all safety evidence is the same. When people talk about biologic drug lymphoma risk, they may be talking about very different kinds of studies. Knowing which kind you are reading about helps you judge a headline.

Individual reports

Doctors, patients and drug makers can send reports of side effects to the FDA. These reports are useful for spotting a possible problem early. But a report only shows that a person took a drug and later had a health problem.

Reports cannot show how many people took the drug without any problem. They also cannot show whether the drug caused the illness. That is why the FDA calls patterns in these reports “potential signals.”

Health-record and database studies

These studies look back at large groups of patients. Researchers compare people who took a drug with people who did not, then count how many in each group were later diagnosed with lymphoma.

Database studies can include tens of thousands of people. Still, the groups are not chosen at random, so other differences between them may explain part of the result.

Randomized trials

In a randomized trial, chance decides who gets which treatment. This makes the groups more alike from the start. When a trial is built to study safety, as the JAK inhibitor trial was, it can give stronger evidence about biologic drug lymphoma risk than reports or database studies alone.

The downside is that trials are costly and take years. Rare cancers like lymphoma may not show up often enough in a trial to give a clear answer.

Relative risk and absolute risk

Many news stories describe biologic drug lymphoma risk as “two times” or “four times” higher. That is relative risk. It compares one group to another. Absolute risk is your actual chance of getting the disease over a period of time.

The NIH explains in its guide to understanding health risks that relative risk alone can be misleading. Its example: a change from 2 in 100 people to 1 in 100 is a 50% relative change, but only a 1% change in absolute terms. When the starting risk is very low, even a large relative increase may still mean a small absolute risk.

Why Biologic Drug Lymphoma Risk Is Hard to Pin Down

Even with good data, scientists often disagree about biologic drug lymphoma risk for years. A few common problems make the question hard to settle.

The disease being treated

People who need a strong drug often have more severe disease. Some severe immune and skin conditions may carry a higher lymphoma risk on their own. Researchers call this “confounding by indication.” It means the reason for treatment, not the drug, may explain part of the link.

Cancer that was already there

Sometimes a cancer starts before treatment but is not found until later. If early lymphoma looks like the disease being treated, a patient may get a new drug for what seems like a flare. The lymphoma is then diagnosed while on the drug, even if it began before.

This is the “unmasking vs causing” question discussed above. It is central to how biologic drug lymphoma risk is studied for Dupixent and CTCL.

More checkups, more diagnoses

People on newer drugs are often watched more closely. More visits can mean more biopsies and more tests. Finding more cancers in a closely watched group does not always mean more cancers are happening.

Small numbers and long timelines

Lymphomas tied to these drugs are usually rare. Rare events need very large groups and long follow-up to study well. Early results can change as more data comes in.

Questions to Ask Your Doctor About Biologic Drug Lymphoma Risk

If you take a biologic or another immune-targeting drug, it is fair to ask how the lymphoma question applies to you. Your doctor knows your history and can help you weigh benefits against risks.

You might ask:

• “What does the current evidence say about biologic drug lymphoma risk for the medicine I take?”
• “Is my condition itself linked to a higher lymphoma risk?”
• “Were there any signs of lymphoma before I started this drug that we should look at again?”
• “Which skin or body changes should make me call you?”
• “How often should I have skin checks, blood work or exams?”
• “If I needed to switch, what other treatments could I consider?”

What to bring to the visit

• A list of every immune-related drug you have used, with rough start and stop dates.
• Dated photos of any patches, bumps or rashes that are not behaving like before.
• A note of new symptoms, such as swollen lymph nodes, night sweats, fever or weight loss.
• Any earlier biopsy or pathology reports you have.

Write down the answers or bring someone who can take notes. If you still feel unsure, asking for a second opinion is a normal step.

A Quick Checklist for Reading Drug Safety Headlines

New studies on immune drugs appear often, and headlines can sound alarming. Before you decide what a story means for you, run through a few simple questions.

1. What kind of study is it? A set of reports, a database study and a randomized trial carry different weight.
2. How many people were studied? Larger groups and longer follow-up give steadier answers for rare cancers.
3. Who was compared? Comparing drug users with people who have the same disease but use a different treatment is more useful than comparing them with healthy people.
4. Is the number relative or absolute? “Four times the odds” sounds large. Ask what the actual chance was in each group.
5. Did the study account for disease severity? Look for words like “adjusted” or “matched,” which mean researchers tried to make the groups more alike.
6. Has anyone repeated it? One study is a starting point. Findings that hold up in several studies are more convincing.
7. Who is reporting it? Medical journals, the FDA and the National Cancer Institute are more reliable than social media posts or ads.

If a study seems to apply to you, bring a copy to your next appointment. Your doctor can explain how it fits with your history and your other risks.

What can happen after a signal

A potential signal can lead to several outcomes. The FDA may decide no action is needed, ask for more study, or update a drug label with new warnings. Each step can take months or years.

For patients, the most useful habit is to watch for official updates rather than rumors. It also helps to keep your own treatment records in order, so you and your doctor can act quickly if anything changes about biologic drug lymphoma risk for your medicine.

Key Terms in Drug Safety Debates

News about biologic drug lymphoma risk often uses technical words. Here is what some of the most common ones mean in plain language.

• Biologic: A drug made from living cells, often given as a shot or infusion. Dupixent, Humira and Remicade are biologics.
• Safety signal: A pattern in reports or data that suggests a drug and a health problem may be linked. It calls for more study. It is not proof.
• Boxed warning: The strongest warning on a U.S. drug label, printed inside a box at the start of the prescribing information.
• Warnings and Precautions: A section of the label that lists serious risks doctors should know about.
• Observational study: A study that looks at what happened to patients without assigning treatment. Database studies are one type.
• Confounding: When a third factor, such as disease severity, explains part of a link between a drug and a disease.
• Association vs causation: An association means two things happen together more often than expected. Causation means one actually causes the other.
• CTCL: Cutaneous T-cell lymphoma, a lymphoma that shows up in the skin. Mycosis fungoides is the most common type.
• HSTCL: Hepatosplenic T-cell lymphoma, the rare lymphoma the FDA flagged with TNF blockers used with certain other drugs.

Knowing these terms makes it easier to follow updates and to ask clear questions. It also helps you tell the difference between a possible concern and a proven finding about biologic drug lymphoma risk.

You do not need to become a scientist to follow this topic. A few plain questions, asked at the right time, can help you and your care team make steady choices as new research comes out.

Whatever you read, do not stop or change a medicine on your own. Talk with the doctor who prescribed it first.

Biologic drug lymphoma risk: frequently asked questions

How Direct2Attorney can help

If you used Dupixent and were later diagnosed with CTCL or another lymphoma, we can connect you with a participating law firm that may review your situation at no cost. Visit our Dupixent lawsuit page to learn more, or read our overview of MDL 3180 and the CTCL science.

Biologic drug lymphoma risk has been debated for decades. Dupixent is the newest chapter, and it is still being written.

Direct2Attorney is a legal marketing and referral service, not a law firm. This article is general information, not legal advice. Submitting information does not create an attorney-client relationship.